Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

Return to Table of Contents

Table 1b. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in children

Combined regimen for treatment of HIV and tuberculosis

PK effect of the rifamycin

Tolerability / toxicity

Antiviral activity when used with rifampin


Super-boosted lopinavir-ritonavir‡ based ART with rifampin-containing tuberculosis treatment

Modest effect


Early favorable experience of super-boosting among young children

Double dose lopinavir-ritonavir is not recommended

Efavirenz-based ART with rifampin-containing tuberculosis treatment

Well-characterized, modest effect

Low rates of discontinuation

Limited study; careful virologic monitoring recommended

Alternative for children >3 years (and >10 kg) for whom super-boosted lopinavir/ritonavir is not tolerated or is contraindicated.

Zidovudine / lamivudine / abacavir with rifampin-containing tuberculosis treatment

50% decrease in zidovudine, possible effect on abacavir not evaluated


Early favorable experience, but this combination is less effective than efavirenz- or nevirapine-based regimens in adults not taking rifampin

Alternative for children <3 years or for patients for whom super- boosted lopinavir/ritonavir is not tolerated or is contraindicated

‡ Super-boosting of lopinavir in children is achieved by giving standard-dose lopinavir/ritonavir plus additional ritonavir to achieve mg for mg parity of ritonavir and lopinavir.

  • Page last reviewed: September 24, 2012
  • Page last updated: December 9, 2013 The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC-INFO